Proprietary Bio‑3D Printing TechCyfuse’s proprietary scaffold-free Bio-3D Printer (Kenzan) is a durable technological advantage that underpins differentiated tissue engineering capabilities. This IP and specialized platform create barriers to entry, support specialized partnerships and research demand, and form the foundation for product and therapeutic development over the coming years.

Strong Revenue Rebound And Commercial TractionA large, sustained revenue rebound signals improving commercial adoption of products or services, showing the business can scale revenue when demand aligns. This durable trend supports continued R&D investment and validates market fit, improving prospects for eventual margin leverage if cost structure is controlled.

Manageable Leverage And Asset BaseReported leverage (debt/equity ~0.48) and a sizable equity base provide balance sheet capacity to fund development and absorb near-term losses. This relative conservatism gives the company runway to pursue clinical/tech milestones and access capital with less immediate insolvency risk versus highly leveraged peers.

Bears Say

Deep, Persistent UnprofitabilityExtremely negative margins indicate the business model is not yet profitable at scale and that cost structure far exceeds revenues. Persistent heavy losses erode equity over time, limit reinvestment capacity, and raise the risk the company must pursue dilutive financing if operational improvements do not materialize.

Consistent Negative Cash GenerationSustained negative operating and free cash flow means operations do not self-fund, forcing reliance on external capital. Over months this raises refinancing and dilution risk, constrains the ability to scale manufacturing or trials, and increases vulnerability to funding-market volatility if cash burn persists.

Rising Debt And Financing RiskMaterial debt growth while losses persist heightens refinancing and interest burdens. Increasing leverage narrows financial flexibility and could force costly or dilutive funding choices if profitability fails to improve, making execution of long-term R&D and commercialization plans more uncertain.

4892 FAQ

What was Cyfuse Biomedical K.K.’s price range in the past 12 months?

Cyfuse Biomedical K.K. lowest stock price was ¥516.00 and its highest was ¥1221.00 in the past 12 months.

What is Cyfuse Biomedical K.K.’s market cap?

Cyfuse Biomedical K.K.’s market cap is ¥6.38B.

When is Cyfuse Biomedical K.K.’s upcoming earnings report date?

Cyfuse Biomedical K.K.’s upcoming earnings report date is May 20, 2026 which is in 72 days.

How were Cyfuse Biomedical K.K.’s earnings last quarter?

Cyfuse Biomedical K.K. released its earnings results on Feb 13, 2026. The company reported -¥12.09 earnings per share for the quarter, missing the consensus estimate of N/A by -¥12.09.

Is Cyfuse Biomedical K.K. overvalued?

According to Wall Street analysts Cyfuse Biomedical K.K.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyfuse Biomedical K.K. pay dividends?

Cyfuse Biomedical K.K. does not currently pay dividends.

What is Cyfuse Biomedical K.K.’s EPS estimate?

Cyfuse Biomedical K.K.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyfuse Biomedical K.K. have?

Cyfuse Biomedical K.K. has 9,970,400 shares outstanding.

What happened to Cyfuse Biomedical K.K.’s price movement after its last earnings report?

Cyfuse Biomedical K.K. reported an EPS of -¥12.09 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.277%.

Which hedge fund is a major shareholder of Cyfuse Biomedical K.K.?

Currently, no hedge funds are holding shares in JP:4892

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.